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Since the onset of the disease, oncologic patients frequently
show a weight loss that varies according to cancer location,
type and stage [1]. The neoplastic diseases that mostly
induce malnutrition are Hodgkin’s lymphoma, gastroin-
testinal cancer, and head and neck tumors [2].
Inversely related to prognosis, malnutrition causes a
worsening in the quality of life, with an increase of mor-
bidity and mortality [3, 4]. In a reasonable percentage of
neoplastic patients, the first cause of death seems to be due
more to a metabolic-nutritional unbalance than to the dis-
ease itself [5].
In a recent French trial in 879 patients, Pressoir et al. [6]
has found that a moderate to severe malnutrition is related
with extended periods of hospitalization: 19.3 ± 19.4 vs.
13.3 ± 19.4 days (P \ 0.001).
In 2010, Platek et al. [7] demonstrated that in patients
with head and neck tumors, who were undergoing an
antiblastic treatment, [10 % pretreatment weight loss was
related with an incomplete locoregional response.
Moreover, in the univariate analysis, malnourished
patients showed a worsened physical function (P = 0.007)
and an increased fatigue (P = 0.034) compared to well-
nourished patients; in the multivariate analysis, instead,
malnutrition was significantly related to physical function
(P = 0.015) [8].
It is known, indeed, that the cytokine unbalances are
already present during the initial diagnosis and continue
over time, leading to the so-called cachexia–anorexia
syndrome, i.e. the tumor–host interaction that determines,
in this disorder as well as in many others, the patient’s
progressive malnutrition.
The nutritional pathway must therefore consider the
tumors in their unitary aspect, in order to continuously take
care of the patient, from the diagnosis to the acute and
chronic consequences of the oncologic therapy, until the
desirable recovery or up to the terminal phase.
According to ASPEN guidelines, it is necessary to
evaluate patient nutritional status, since the beginning of
the diagnostic–therapeutic course, carefully controlling it
throughout the treatment, and changing it when specific
needs are required [9].
A survey conducted by CERGAS-Bocconi in 787
patients of 110 Cancer Treatment Centers has pointed out
that oncologists poorly understand the discomfort of
patients who are unable to communicate it, and they mostly
take into consideration symptoms like nausea (62 %), pain
(53 %) instead of depression, frequently ignored (15 %),
and fatigue (30 %).
Malnutrition in cancer patients is defined as neoplastic
cachexia–anorexia syndrome and is characterized by
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weight loss, adynamia, anorexia, hyporexia and asthenia. This
condition shows a multifactorial pathogenesis including food
intake reduction (often associated with appetite and taste
changes, disease-related diet depletion, and psychological
distress), tumor–host interaction (through tumoral cachexia-
inducing substances, neuroendocrine mechanisms and cyto-
kine network changes) and side effects caused by anti-cancer
treatments [chemotherapy (CT), radiotherapy (RT), surgery].
As a result, changes in energy, protein, lipid and glucose
metabolism are observed.
For this reason, a failed adaptation of neoplastic patients
marks the changes in the body composition, with extra-
cellular mass expansion, cellular and fat mass reduction, as
well as energy loss.
The nutritional status of neoplastic patients is directly
related to chemotherapy tolerability, therefore to its effi-
cacy, and to patient’s quality of life. A questionnaire pro-
viding a correct nutritional assessment, and the patient
biological findings enable the planning of a correct diet.
This strategy allows the improvement in chemotherapy
tolerability and patient’s quality of life.
Based on such considerations, the need of a multidisci-
plinary approach in the management of onco-hematological
patients arises, through the collaboration of onco-hematolo-
gists, nutritionists, psychologists, chemists, nurses, dietitian,
as well as social workers and physiotherapists.
The nutritional assessment of cancer patients includes a
careful history (medical, nutritional and pharmacological),
physical examination with anthropometric measurements
(present weight, usual weight, weight loss during the last
6 months, upper arm muscle circumference, triceps skinfold),
laboratory test (albumin, total proteins, transferrin, prealbu-
min, lymphocytes), functional test (dynamometry) and caloric
consumption test, with possible measure of physical activity
level (PAL), that corresponds to the total energy expenditure/
resting energy expenditure (TEE/REE) ratio.
Finally, considering a holistic-nutritional approach, the
assessment of quality of life is essential (by means of
specific questionnaires like EORTC, SPITZER and TQ).
All these outcomes can be collected in indexes, where a
defined score is assigned to each parameter. The sum or the
product derived will enable to classify malnutrition in a
specific grading (mild, moderate, severe).
Among these, most utilized and validated items are
Subjective Global Assessment (SGA), Patient-generated
SGA (PG-SGA), MUST and Nutritional Risk Index (NRI).
Are the outcomes related to nutritional therapy
evaluated? If so, in which way?
The nutritional intervention strategy in cancer patients
obviously implies a suitable initial evaluation through a
screening that defines the malnutrition severity. According
to malnutrition staging, the patient will be inserted in a
specific therapeutic and diagnostic program.
In case of normal nutritional status, the patient will be
monitored each month; in case of mild malnutrition, the
patient will undergo further nutritional assessment and
dietetic history, as to allow a tailored nutritional counsel-
ing; in case of moderate–severe malnutrition, the patient
will be treated with multimodal therapies (anti-anorexic
agents, dietetic/artificial integration, prokinetic and antie-
metic drugs). In order to evaluate the nutritional support
efficacy in cancer patients, anthropometric, biochemical,
functional and metabolic data should be analyzed, as well
as performance status, quality of life and psychological
findings.
For instance, one of the primary outcomes is the eval-
uation of body weight; however, it is important that the
weight gain reflects the increase of metabolically active
tissue. For this reason, the simple quantitative assessment
of body weight can be misleading, because it does not
assess the body qualitative composition (i.e. fat mass
increase versus lean one) or the hydration status of patients
(presence of ascites or edema).
Also the metabolic status have to be evaluated: patient
with cancer show an increased REE; this depends on tumor
mass, cancer type, chemotherapy drugs, disease duration
and patient nutritional status. Published trials have shown
that nutritional supply with certain substances can increase
TEE/REE ratio, improving PAL.
Another important finding is the determination of perfor-
mance status: the Karnofsky index (KI) measures, in per-
centage from 0 to 100, the patient’s capability to carry out
daily activities and the probable need of assistance support.
Also quality of life, certainly influenced by body weight,
is evaluated, since the progressive neoplastic cachexia can
lead to depression, asthenia and anxiety, with relevant loss
in appetite and caloric intake (useful assessment instru-
ments are EORTC-ALA-30, Spitzer index, TIQ (Therapy
Impact Questionnaire).
Finally MUST, PG-SGA, SGA assessments scales are
utilized, since they are useful till the onset of disease, as
first nutritional screening methods, and after, as evaluation
tools of re-nutrition effects.
The fatigue
The fatigue is the most common chronic symptom in
cancer patients.
An exact definition of fatigue does not exist, since
common notion of tiredness sometimes overlaps the clini-
cally relevant symptom of fatigue. It can be defined as the
difficulty to start and sustain voluntary activities [10].
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The peripheral fatigue can be clinically distinguished from
the central fatigue. The first defines the muscle fatigue due to
alterations of muscles or of neuromuscular junction; it is
objectively defined, measured by the force peak decline rate
produced during the maximum voluntary muscle contraction
and it is evaluated by electromyography.
Peripheral fatigue is typically observed in case of
myasthenia, metabolic myopathies, mitochondrial myopa-
thies and hypothyroidism.
Central fatigue shows a feeling of constant exhaustion.
Its severity is independent of the nature and severity of
underlying diseases (like MS, Parkinson’s disease,
migraine, mitochondrial diseases, etc.), and it undergoes
periodic fluctuations in relation to different psychological
or physiological stimuli. In a study conducted by Ashbury
et al. [11], 913 patients were treated with antiblastic ther-
apy for 2 years; the fatigue, reported in 78 % of patients,
worsened the normal daily activities in 71 % of the cases.
In patients with metastatic cancer, fatigue is present in
more than 75 % of cases, and finally, according to Hop-
wood (in a multicenter, randomized study in patients with
lung cancer, aged 39–90 years), fatigue and weakness were
Table 1 Baseline
characteristics of a sample of
144 cancer patients undergoing
treatment (lung 68, stomach 30,
esophagus 12, pancreas 31) [12]
Hgs hand grip strength
Mean Standard
deviation
Median Percentile 25 Percentile 75 N (%)
Age 68 10 70 63 76
Usual weight 72 15 70 62 83
Present weight 66.9 14.6 64.8 56.9 76.0
%Weight loss 6.166 8.389 4.430 0.122 11.911
Height (m) 1.68 0.11 1.69 1.61 1.73
BMI 23.6 4.4 23.0 20.5 26.2
CMB (cm) 26.5 4.2 27.0 24.0 29.0
Triceps skinfold (cm) 12.4 7.3 10.0 7.0 14.4
hgs dx 26 9 25 20 32








Fatigue 6.055 2.067 6.255 4.550 7.590
VAS appetite 6 3 6 4 8
VAS nausea 2 3 0 0 5
VAS pain 3 3 3 0 5
Blood glucose (mg/dl) 126 48 109 96 141
Creatinine (mg/dl) 1.3 5.1 0.8 0.7 1.0
Blood urea (mg/dl) 39.17 15.73 35.00 29.00 45.00
Tot. proteins (g/l) 49.830 28.260 63.000 7.250 69.000
Albumin (g/l) 27.87 12.33 33.00 25.00 36.00
Transferrin (mg/dl) 235.111 55.797 228.000 202.000 251.000
Cholinesterase (UI/ml) 6,208.58 1,985.47 6,100.00 4,800.00 7,300.00
CPR 13.39 19.40 6.20 1.90 12.30
Lymphocytes (mm3) 2.04 2.33 1.74 1.24 2.28
REE kcal tot (HB) 1,770 253 1,728 1,600 1,900
Prot requirements 82 16 82 71 91
kcal intake 1,459 434 1,434 1,183 1,711
Prot intake 69.2 90.7 60.0 46.0 74.2
Hydric intake 1,029.02 535.35 1,000.00 500.00 1,500.00
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observed in[80 % of patients. Fatigue, therefore, involves
all stages of the disease and can persist even several
months after the accomplishment of the therapy and con-
siderably after recovery. This element is common to the
other form of pathological fatigue: chronic fatigue syn-
drome (CFS). Cancer-related fatigue (CRF) results in the
worsening of patients’ quality of life, can cause treatment
discontinuation, and may increase health care management
costs. However, fatigue is often poorly considered by cli-
nicians, whose attention is mainly focused on pain and
disease-free survival, despite the significant impact of
fatigue on patient’s quality of life. In patients older than
70 years, the fatigue is present in 70–99 % of cases.
In 144 treated patients with cancer of lung, esophagus,
stomach and pancreas (Table 1), very recent data from our
group (ONCONUT project), which evaluated the impact
of Whey protein (Prother—Spepharm Italia) supplement
on fatigue in cancer patients, show a low positive corre-
lation between fatigue and weight loss (r = 0.224)
(Table 2) [12].
A significant inverse relationship exists between fatigue
and Karnofsky status (r = -0.46, P \ 0.001): when one
value increases, the other one decreases, and vice versa.
A positive, but low correlation, and therefore a weak
direct relationship, exists between fatigue and pain
(r = 0.354, P \ 0.001).
The clinical nutrition represents a supportive element to
cancer treatment, and its goal, synergistic to it, is to reach
the cure.
Therefore, in cancer patients, the therapeutic nutrition
course reproduces the specific clinical intervention and
integrates with it in a constant over time continuum, in the
light of typical therapeutic goals of oncology: survival,
symptoms control and improved quality of life. Considering
the future therapeutic strategies in oncology and the rele-
vant goals in terms of quality of life, it is mandatory not
only to seek even more effective and ‘‘smart’’ chemother-
apies, but also to limit the incidence of related toxic effects,
by a more accurate study of oxidative stress and substances
able to antagonize its consequences.
According to the general project, the ‘‘parallel meta-
bolic-nutritional approach’’, as suggested by Muscaritoli
et al. [13] activated in cancer patients, must be structured in
parallel to the anti-neoplastic treatment, and the early
involvement of a dietitian in the oncology team offers the
advantage of an easy and rapid contact with patients
referring to the oncological structure.
The nutritional intervention, according to the ONCO-
NUT Group pathway [12], must be articulated through:
• carrying out a nutritional screening in order to assess
the risk of malnutrition,
• history of weight and possible weight loss,
• careful history of usual intake of food protein–calories,
and 24 h recall,
• evaluation of present coverage percentage versus
calculated protein–calories requirements,
• detection of symptoms linked to food ingestion and to
any gastrointestinal disorder,
• execution of functional tests: hand grip strength evaluation,
• assessment of fatigue, quality of life and performance
status.
Information and strategies must be given to patients to
be able to feed properly and adequately. Indeed, the liter-
ature has demonstrated that the dietary counseling, when
compared with a diet ad libitum or with nutritional sup-
plementation, is able to improve the prognosis and the QoL
of cancer patients [14].
Table 2 Correlations between
fatigue, weight loss, appetite,
pain and Karnofsky status in
144 cancer patients in
therapeutic phase [12]
Patients (n = 144) Fatigue %Weight loss VAS appetite VAS nausea VAS pain Karnofsky
Fatigue
Pearson 0.224 -0.139 0.238 0.354 -0.462
P value 0.007 0.097 0.004 0.000 0.000
%Weight loss
Pearson -0.081 0.000 0.066 -0.526
P value 0.332 1.000 0.434 0.000
VAS appetite
Pearson -0.130 -0.152 0.172
P value 0.122 0.069 0.039
VAS nausea
Pearson 0.408 -0.233
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If the simple counseling is not enough to achieve the
requirements, the goal of the clinical nutritionist is to plan a
more complete nutritional assessment in dietetics and
clinical nutrition structures, for a more articulated nutri-
tional intervention, with possible prescription of artificial
oral supplementation, and/or activation of enteral and/or
parenteral nutrition.
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Creative Commons Attribution License which permits any use, dis-
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